Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire•10/11/2026•07:00 ET
0
Key Highlights
- ➤$430.2 million cash, runway expected into 2029
- ➤SOLARA Phase 3 initiated for once-weekly subcutaneous sutacimig in GT
- ➤Sutacimig shortened prothrombin time more than 50% in both FVIID participants
- ➤HMB-003 Phase 1 dosed first participant for heavy menstrual bleeding
- ➤$27.3 million third-quarter net loss, or $0.58 per share
Expert Statements
Benny Sørensen, MD, PhD, CEO of Hemab Therapeutics
“We are excited to have started our Phase 3 study in Glanzmann thrombasthenia, transitioning Hemab to a biotech company with clinical stage programs ranging from Phase 1 to Phase 3 across our portfolio.”
Benny Sørensen, MD, PhD, CEO of Hemab Therapeutics
“As our programs advance, we continue to expand our development efforts for larger, underserved markets across coagulation disorders, from the high-severity populations we started with to conditions like heavy menstrual bleeding that affect millions of women each year.”
Benny Sørensen, MD, PhD, CEO of Hemab Therapeutics
“We are also excited to have dosed our first participant in the Phase 1 trial of HMB-003 in heavy menstrual bleeding, and look forward to sharing additional preclinical and clinical data from all three programs in the coming months.”
Dosed first participant in Phase 1 clinical trial of HMB-003 for management of heavy menstrual bleeding, a condition affecting more than 23 million women in the U.S. alone
Announced data showing HMB-003 reduced severe menstrual bleeding in a cynomolgus monkey model; data to be presented at the 68th ASH Annual Meeting and Exposition in December 2026
Get started
Create a free account to read the full story.